Core Natural Resources

IRBM Develops Novel Allosteric Inhibitor Targeting Zika Virus Protease with Broad Flavivirus Potential

- IRBM has discovered a novel allosteric inhibitor targeting the Zika virus NS2B-NS3 protease, published in Nature Communications, representing a promising new therapeutic approach. - The small molecule demonstrated significant antiviral activity in animal models with favorable safety and pharmacokinetic profiles, supporting potential clinical development. - The inhibitor's mechanism may extend to other flaviviruses including dengue, yellow fever, and West Nile virus, suggesting broader therapeutic applications. - This breakthrough addresses a critical unmet medical need as no approved antivirals or vaccines currently exist for Zika virus infections.